Abstract:Single‐cell RNA sequencing analyses and imaging mass cytometry reveal increased hyperactivated Th1‐biased response and decreased immunosuppressive Treg in the IC/BPS. Pro‐inflammatory cytokines and TNF‐α from macrophages and IL6 from fibroblasts are identified as key mediators of IC/BPS pathogenesis. This study provides an essential resource for diagnosis and treatment of IC/BPS by highlighting the importance of the microenvironment of bladder mucosa.Interstitial cystitis/bladder pain syndrome (IC/BPS) has a significant impact on quality of life, but the etiopathogenesis remains largely unknown. The bladder microenvironment of patients with IC/BPS to obtain biological evidence supporting diagnosis and novel therapy is systematically characterized. Single‐cell RNA sequencing (scRNA‐seq) and image mass cytometry (IMC) are applied to bladder biopsies of the IC/BPS cohort. A total of 42 distinct cell clusters are identified from different groups. The increased hyperactivated Th1‐biased response, but not Th2‐biased response, and decreased immunosuppressive Treg are elucidated in the bladder microenvironment of non‐Hunner‐type IC (NHIC)/Hunner‐type IC (HIC). M2/M2‐like macrophage extends in the HIC and M1‐like macrophage extends in NHIC, all of which secrete a range of chemokines with different pattern. The pro‐inflammatory mediators, TNF‐α, produced by tissue‐resident macrophages and IL6, by the inflammatory fibroblasts are identified as key mediators of IC/BPS pathogenesis. Additionally, a regulatory network between different cell types is observed as a shift from structural cell communication in unaffected normal bladder to a Macrophage‐Endothelial‐dominated interactome in NHIC/HIC. The results demonstrate the high heterogeneity in NHIC/HIC, and provide an essential resource for diagnosis, and treatment of IC/BPS in the future by highlighting the importance of the microenvironment of bladder mucosa.

Purine nucleoside phosphorylase as a target for the treatment of interstitial cystitis/bladder pain syndrome with and without Hunner lesions

The Pathomechanism and Current Treatments for Chronic Interstitial Cystitis and Bladder Pain Syndrome

Urinary Biomarkers in Interstitial Cystitis/Bladder Pain Syndrome and Its Impact on Therapeutic Outcome

Promising Experimental Treatment in Animal Models and Human Studies of Interstitial Cystitis/Bladder Pain Syndrome

Stem cell therapy for interstitial cystitis/bladder pain syndrome

Purine nucleoside phosphorylase inhibition is an effective approach for the treatment of chemical hemorrhagic cystitis

Interstitial Cystitis/Bladder Pain Syndrome: a Review and an Update

A Hypothesis for Anatomical Pathways of Chronic Pelvic Pain of "Unknown Origin"

Identification of Key Genes in Human Urothelial Cells Corresponding to Interstitial Cystitis/bladder Pain Syndrome in a Lipopolysaccharide-Induced Cystitis Model.

UPK3A+ umbrella cell damage mediated by TLR3–NR2F6 triggers programmed destruction of urothelium in Hunner‐type interstitial cystitis/painful bladder syndrome

PACAP/PAC1 Regulation in Cystitis Rats: Induction of Bladder Inflammation Cascade Leading to Bladder Dysfunction

Multi‐omics analyses uncover metabolic signatures and gene expression profiles of interstitial cystitis/bladder pain syndrome

Hypertension and urologic chronic pelvic pain syndrome: An analysis of MAPP-I data

Potential Urine and Serum Biomarkers in Patients with Bladder Pain Syndrome/Interstitial Cystitis

Molecular pathogenesis of interstitial cystitis/bladder pain syndrome based on gene expression

Latest insights into the pathophysiology of bladder pain syndrome/interstitial cystitis

Treatment approaches for painful bladder syndrome/interstitial cystitis

The role of TSG-6 and uroplakin III in bladder pain syndrome/ interstitial cystitis in rats and humans

Intravesical injections of autologous platelet‐rich plasma for the treatment of refractory interstitial cystitis

Urinary Diversion for Intractable Interstitial Cystitis/bladder Pain Syndrome: Whether the Transvaginal Urethrectomy Can Play a Part

Multimodal Single‐Cell Analyses Outline the Immune Microenvironment and Therapeutic Effectors of Interstitial Cystitis/Bladder Pain Syndrome